Key result
Transfemoral TAVI without predilatation was feasible, achieving 100% procedural success and 0% 30-day mortality, with significantly reduced radiation and contrast dye compared to predilatation.
Why the study?
Does transfemoral TAVI without predilatation improve procedural safety and feasibility compared to TAVI with predilatation in patients with native aortic valve stenosis?
Cohort (n=56)
Does transfemoral TAVI without predilatation improve procedural safety and feasibility compared to TAVI with predilatation in patients with native aortic valve stenosis?
Transfemoral TAVI without predilatation using a balloon-expandable valve is feasible, safe, and reduces radiation and contrast use compared to standard predilatation.
Answers are grounded in this paper and cite their sources.
May support omitting predilatation to reduce radiation and contrast; hypothesis-generating and requires randomized confirmation before practice change.
BACKGROUND: Transcatheter aortic valve implantation (TAVI) without predilatation has fewer procedural steps and thereby potentially fewer complications. This has been demonstrated for the antegrade transapical access; however, whether TAVI can be safely performed without predilatation using the retrograde transfemoral route is unknown. HYPOTHESIS: We postulated that TAVI is feasible with a balloon-expandable device without predilatation using the retrograde transfemoral route. METHODS: Twenty-six consecutive patients with stenosis of the native aortic valve (AV) undergoing transfemoral TAVI with the Edwards SAPIEN XT prosthesis without predilatation were enrolled in this retrospective study and compared with 30 patients treated previously with predilatation. RESULTS: The procedure was successfully performed in all 26 patients, irrespective of the AV area and the extent of AV calcification. At baseline mean AV area, mean AV gradient, and median left ventricular ejection fraction were 0.7 ± 0.2 cm(2) , 36.0 ± 17.3 mm Hg, and 55.0% (interquartile range [IQR], 35.0-60.0], respectively; prior to discharge these values were 1.7 ± 0.3 (P < 0.001), 9.8 ± 6.1 mm Hg (P < 0.001), and 57.5% (IQR, 38.7-60.0) (P = not significant). Postdilatation was required in 3 patients due to aortic regurgitation > 2°; this was reduced by the procedure to < 2° in all cases. Radiation dose and amount of contrast dye were significantly reduced in comparison with the predilatation group. No periprocedural neurological adverse events occurred. Mortality at 30 days was 0%. CONCLUSIONS: TAVI without predilatation using the transfemoral Edwards SAPIEN XT valve is feasible and safe. Larger studies are required to further evaluate this approach.
No takes yet. Share an insight, caveat, or question.
Möllmann et al. (2014) conducted a cohort in Stenosis of the native aortic valve (n=56). Transfemoral TAVI without predilatation vs. Transfemoral TAVI with predilatation was evaluated on Procedural success. Transfemoral TAVI without predilatation was feasible, achieving 100% procedural success and 0% 30-day mortality, with significantly reduced radiation and contrast dye compared to predilatation.
Synapse has enriched 10 related papers. Consider them for comparative context: